Dômont Julien, Soria Jean-Charles, Le Chevalier Thierry
Department of Medicine, Institut Gustave-Roussy, Villejuif, France.
Semin Oncol. 2005 Jun;32(3):279-83. doi: 10.1053/j.seminoncol.2005.02.018.
Approximately 80% of lung malignancies are non-small cell lung carcinoma (NSCLC). Patients diagnosed with early-stage disease (about 30% of patients) undergo surgery, but up to 50% develop local or distant recurrence. In an effort to improve survival for patients with resectable NSCLC, chemotherapy has been explored in the adjuvant setting. Several adjuvant trials were launched in the mid 1990s after an individual data-based meta-analysis suggested a 5% survival benefit at 5 years. Among those, the International Adjuvant Lung Cancer Trial (IALT) study, with 1,867 patients included, confirmed the benefit of postoperative chemotherapy in resected NSCLC. More recently, modern platinum-containing doublets showed a 10% to 15% overall benefit compared to no adjuvant treatment. In this article, the current status of adjuvant chemotherapy is reviewed, and future prospects are discussed.
大约80%的肺癌为非小细胞肺癌（NSCLC）。被诊断为早期疾病的患者（约占患者总数的30%）会接受手术，但高达50%的患者会出现局部或远处复发。为了提高可切除NSCLC患者的生存率，人们在辅助治疗中探索了化疗。在一项基于个体数据的荟萃分析表明5年生存率有5%的获益后，20世纪90年代中期开展了几项辅助试验。其中，纳入1867例患者的国际辅助肺癌试验（IALT）研究证实了术后化疗对可切除NSCLC的益处。最近，与不进行辅助治疗相比，现代含铂双药方案显示出10%至15%的总体获益。本文对辅助化疗的现状进行了综述，并讨论了未来前景。
